Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla eyes filing over...

    Cipla eyes filing over 20 ANDAs in US this fiscal

    Written by Ruby Khatun Khatun Published On 2017-08-02T09:25:56+05:30  |  Updated On 2 Aug 2017 9:25 AM IST
    Cipla eyes filing over 20 ANDAs in US this fiscal

    New Delhi: Drug major Cipla has said it is looking to file more than 20 applications seeking approval for its generic medicines from the US health regulator this fiscal.


    In the last financial year, the company had filed 32 abbreviated new drug applications (ANDAs) in the US.


    An ANDA contains data that provides for review and ultimate approval of a generic drug product by the US Food and Drug Administration (USFDA).


    "In the US, we are eyeing over 20 ANDA filings, strengthening the execution of key launches, and building our speciality focus in respiratory and CNS," Cipla MD and CEO Umang Vohra said in a message to the shareholders in the Annual Report 2016-17.


    According to the report, Cipla has identified Respiratory and Central Nervous System (CNS) in speciality segment as its core focus therapy areas with an aim to further accelerate growth in the US market.


    The company said it will continue to focus on investing towards building its speciality franchise through a combination of development within the company and inorganic opportunities.


    Besides, Cipla will also work towards bolstering leadership position in India, South Africa, and key Emerging Markets, Vohra said.


    "Our biggest imperative in FY18 will be to generate sustainable and profitable top-line growth, and to build a strong organisation," he added.


    Given the challenges related to GST and certain key product launches in the US market, the company expects higher growth in the second half of the next fiscal, the report said.

    20 ANDAsabbreviated new drug applicationsCentral Nervous SystemCiplafilegenericGSTmedicinesUmang VohraUSUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok